These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10379623)

  • 1. Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene.
    Walker EA; Tiano MJ; Benyas SI; Dykstra LA; Picker MJ
    Psychopharmacology (Berl); 1999 May; 144(1):45-53. PubMed ID: 10379623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
    Picker MJ
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine.
    Negus SS; Brandt MR; Gatch MB; Mello NK
    Drug Alcohol Depend; 2003 May; 70(1):17-27. PubMed ID: 12681522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
    Heyman JS; Mulvaney SA; Mosberg HI; Porreca F
    Brain Res; 1987 Sep; 420(1):100-8. PubMed ID: 2823970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal by beta-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig.
    Hayes AG; Birch PJ
    Neuropharmacology; 1988 Aug; 27(8):813-6. PubMed ID: 3216959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E; Yaksh TL
    J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.
    Hayes AG; Skingle M; Tyers MB
    Br J Pharmacol; 1986 Aug; 88(4):867-72. PubMed ID: 3017495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
    Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
    Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of the response rate-decreasing effects of meperidine and morphine by beta-funaltrexamine and naltrexone in squirrel monkeys.
    Hughes CE; Dykstra LA
    Drug Alcohol Depend; 1997 May; 45(3):197-206. PubMed ID: 9179521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
    Steinmiller CL; Young AM
    Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-funaltrexamine antagonizes the discriminative stimulus effects of morphine but not naltrexone in pigeons.
    France CP; Woods JH
    Psychopharmacology (Berl); 1987; 91(2):213-6. PubMed ID: 3107034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic sucrose intake reduces the antagonist effect of beta-funaltrexamine on morphine-induced antinociception in female but not in male rats.
    Coy RT; Kanarek RB
    Nutr Neurosci; 2006; 9(3-4):131-9. PubMed ID: 17176635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
    Gouardères C; Jhamandas K; Sutak M; Zajac JM
    Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
    Allen RM; Dykstra LA
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
    Paronis CA; Waddell AB; Holtzman SG
    Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
    Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
    Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes.
    Jiang Q; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Mosberg HI; Porreca F
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1069-75. PubMed ID: 1646319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.